MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

80.97
+2.11
+2.68%
After Hours: 81.04 +0.07 +0.09% 17:36 05/27 EDT
OPEN
79.00
PREV CLOSE
78.86
HIGH
81.20
LOW
78.65
VOLUME
659.47K
TURNOVER
0
52 WEEK HIGH
94.20
52 WEEK LOW
71.59
MARKET CAP
14.98B
P/E (TTM)
526.81
1D
5D
1M
3M
1Y
5Y
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 18h ago
9 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Benzinga · 05/18 17:36
BioMarin Pharmaceutical (NASDAQ:BMRN shareholders incur further losses as stock declines 4.9% this week, taking five-year losses to 14%
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to...
Simply Wall St. · 05/11 11:32
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB), considered a proxy for the sector, shed close to 3 pe...
Benzinga · 05/09 12:33
BRIEF-Biomarin Pharmaceutical Inc - Humaira Serajuddin Named To Newly Created Role Of Senior Vice President, Chief Marketing Officer
reuters.com · 05/05 20:05
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise. Humaira Serajuddin was named Senior Vice President, Chief Marketing Officer and Erin Burkhart was...
PR Newswire · 05/05 20:04
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation ...
PR Newswire · 05/05 12:29
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas. To access the live webc...
PR Newswire · 05/04 13:00
More
No Data
Learn about the latest financial forecast of BMRN. Analyze the recent business situations of Biomarin Pharmaceutical Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
47.62%Buy
9.52%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BMRN stock price target is 116.78 with a high estimate of 176.00 and a low estimate of 90.00.
High176.00
Average116.78
Low90.00
Current 80.97
EPS
Actual
Estimate
-0.100.120.340.57
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 795
Institutional Holdings: 195.23M
% Owned: 105.53%
Shares Outstanding: 185.00M
TypeInstitutionsShares
Increased
186
14.19M
New
78
1.67M
Decreased
185
13.01M
Sold Out
65
2.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Jean-Jacques Bienaime
Chief Financial Officer/Executive Vice President - Finance
Brian Mueller
Corporate Executive
Henry Fuchs
Executive Vice President/Chief Technology Officer
C. Greg Guyer
Executive Vice President/General Counsel/Secretary
G. Eric Davis
Executive Vice President
Jeff Ajer
Senior Vice President/Chief Marketing Officer
Humaira Serajuddin
Chief Accounting Officer/Vice President
Erin Burkhart
Lead Director/Independent Director
Richard Meier
Independent Director
Mark Alles
Independent Director
Elizabeth Anderson
Independent Director
Willard Dere
Independent Director
Elaine Heron
Independent Director
Maykin Ho
Independent Director
Robert Hombach
Independent Director
V. Bryan Lawlis
Independent Director
David Pyott
Independent Director
Dennis Slamon
No Data
No Data
About BMRN
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Webull offers kinds of BioMarin Pharmaceutical Inc. stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.